Beyond Paxlovid: The Urgent Need for Better Meds

There's no way to overdo it.

Yes, there's hope in the fight against Long Covid.

Hope doesn't come in the form of natural immunity or subpar vaccines rolled out after waves of illness have already peaked. It comes in the form of clean indoor air, widespread masking, and better treatments. In that vein, the NIH is finally launching a new batch of clinical trials focused on Long Covid, five total, dedicated to different aspects of the condition. Institutes like Mount Sinai are running clinical trials on repurposed HIV drugs. So is HealthBio, a startup working on immune diseases. (They're testing maraviroc and atorvastatin.) Post-Viral Trials News is sharing updates as they roll in. Of course, the NIH and FDA need steady pressure to make sure they're funding trials that focus on a range of options. Given the urgency of the crisis, we should be doing far more. As Harvard economist David Cutler has said on developing treatments for Long Covid, "There is no amount that's overdoing it." We're talking about a $16 trillion …